comparemela.com

Latest Breaking News On - Athira pharma inc - Page 5 : comparemela.com

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

BOTHELL, Wash., Feb. 08, 2024 (GLOBE NEWSWIRE) Athira Pharma, Inc. ATHA, a late clinical-stage biopharmaceutical company focused on developing small…

Dr Leen Kawas Details How Management Diversity Can Drive Better Company Performance

Dr. Leen Kawas, Managing General Partner at Propel Bio Partners, highlights the myriad of ways in which a diverse management team can positively impact an entire workforce. In today’s increasingly global business landscape, workers with different nationalities and cultural profiles often come together to help achieve a company’s mission. Individuals…

With 36% ownership, Athira Pharma, Inc (NASDAQ:ATHA) has piqued the interest of institutional investors

Key Insights Significantly high institutional ownership implies Athira Pharma's stock price is sensitive to their.

Mark James Litton Sells 4,820 Shares of Athira Pharma, Inc (NASDAQ:ATHA) Stock

Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) CEO Mark James Litton sold 4,820 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $2.91, for a total value of $14,026.20. Following the sale, the chief executive officer now directly owns 144,397 […]

Contrasting Athira Pharma (NASDAQ:ATHA) & Scinai Immunotherapeutics (NASDAQ:SCNI)

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Athira Pharma (NASDAQ:ATHA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.